GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress

- Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year -

- Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of sales -

- Conference call today at 4:30 p.m. EST -

LONDON and CARLSBAD, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces financial results for the fourth quarter and full-year ended December 31, 2019.

“2019 was an exceptional and transformative year for GW, led by the successful launch of Epidiolex in the US and approval in Europe. The positive impact this medicine has had on thousands of patients and their families provides a compelling foundation for continued growth in 2020,” said Justin Gover, GW’s Chief Executive Officer. “We also expect 2020 to be an important year for our growing and developing product pipeline beyond Epidiolex as we build on our world leadership in cannabinoid science. We are focused on advancing nabiximols in the US in several indications and clinical programs with other potential products whilst continuing to bring Epidiolex to more patients in the US and Europe.”


  • Significant progress with Epidiolex (cannabidiol)
    • Total net product sales of Epidiolex of $104.5 million for the fourth quarter and $296.4 million for the full year
    • U.S. commercial update
      • 2020 focus on broadening prescriber base, expanding payer coverage, entering long term care segment, and expected launch of TSC indication
    • European launch underway
      • German commercial launch in Q4 2019
      • Secured positive NICE recommendation in the UK with commercial launch in Q1 2020
      • Commercial launches in France, Spain and Italy expected later this year, following pricing and reimbursement
    • Clinical progress with further indications – broadening addressable market
      • Tuberous Sclerosis Complex (TSC) sNDA filed with FDA earlier this month and MAA submission to EMA expected in Q1 2020
      • Phase 3 trial in Rett Syndrome recruiting
      • Several new formulations of CBD advancing into additional Phase 1 studies in 2020, including modified oral solution, and capsule
    • Improved intellectual property rights and exclusivity
      • In addition to orphan exclusivity, 9 granted patents listed in “Orange Book” and align directly with Epidiolex FDA label with expiry dates to 2035
      • Epidiolex composition patent application recently published
      • 2 new allowed patents broadly covering use in LGS and Dravet syndrome
      • Additional patent applications under review, including patents related to the use of Epidiolex in TSC and other indications
  • Pipeline progress
    • Nabiximols (Sativex® outside of the US)
      • Multiple Sclerosis spasticity -3 positive Phase 3 trials completed in Europe
        • US pivotal clinical program expected to commence in Q2 2020 to augment existing data package
      • Spinal cord injury spasticity - clinical program expected to commence in H2 2020
      • PTSD – clinical program expected to commence in H2 2020
    • Schizophrenia (GWP42003)
      • Positive Phase 2a trial published and Phase 2b trial expected to commence H1 2020
    • CBDV in autism
      • 30-patient open label study in autism underway. Initial data expected in 2020.
      • Investigator-led 100 patient placebo-controlled trial in autism underway
      • Open label study in Rett syndrome and seizures underway
    • Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD program
      • Phase 1b safety study in patients underway
      • Orphan Drug and Fast Track Designations granted from FDA and EMA


  • Total revenue for the quarter ended December 31, 2019 was $109.1 million compared to $6.7 million for the quarter ended December 31, 2018
  • Net loss for the quarter ended December 31, 2019 was $24.9 million compared to a net loss of $71.9 million for the quarter ended December 31, 2018
  • Cash and cash equivalents at December 31, 2019 were $536.9 million compared to $591.5 million as of December 31, 2018

Conference Call and Webcast Information
GW Pharmaceuticals will host a conference call and webcast today at 4:30 pm EST. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company’s website at A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-481-4010 or 919-882-2331 (international). For both dial-in numbers please use conference Replay ID: 33178.

About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution CV, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age or older. This product has received approval in the European Union under the tradename EPIDYOLEX®. The Company has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) to expand the indication for Epidiolex to include seizures associated with Tuberous Sclerosis Complex, for which it has reported positive Phase 3 data, and is carrying out a Phase 3 trial in Rett syndrome. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as for the treatment of PTSD. The Company has additional cannabinoid product candidates in Phase 2 trials for autism and schizophrenia. For further information, please visit

Forward-looking statements
This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of EPIDIOLEX®/EPIDYOLEX® (cannabidiol) oral solution CV and Sativex® (nabiximols), and the safety profile and commercial potential of both medicines. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, and the acceptance of EPIDIOLEX®/EPIDYOLEX®, Sativex® and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


GW Pharmaceuticals plc 
Stephen Schultz, VP Investor Relations917 280 2424 / 401 500 6570
U.S. Media Enquiries:
Sam Brown Inc. Healthcare Communications
Christy Curran
Mike Beyer
615 414 8668
312 961 2502
Ex-U.S. media enquiries 
Ben Atwell, FTI Consulting+44 (0)203 727 1000

(in thousands, except share data)

  December 31,  December 31, 
  2019  2018 
Cash and cash equivalents $536,933  $591,497 
Accounts receivable, net  48,883   4,192 
Inventory  85,528   33,030 
Prepaid expenses and other current assets  28,292   17,903 
Total current assets  699,636   646,622 
Property, plant, and equipment, net  127,765   90,832 
Operating lease assets  24,916    
Goodwill  6,959   6,959 
Deferred tax assets  18,123   8,720 
Other assets  4,850   2,935 
Total assets $882,249  $756,068 
Liabilities and stockholders equity        
Accounts payable $9,990  $9,796 
Accrued liabilities  99,374   52,477 
Current tax liabilities  437   2,384 
Other current liabilities  7,760   1,559 
Total current liabilities  117,561   66,216 
Long-term liabilities:        
Finance lease liabilities  5,573   5,690 
Operating lease liabilities  21,650    
Other liabilities  11,431   10,082 
Total long-term liabilities  38,654   15,772 
Total liabilities  156,215   81,988 
Commitments and contingencies        
Stockholders’ equity:        
Ordinary shares par value £0.001; 371,068,436 and 366,616,688 shares
 outstanding as of December 31, 2019 and 2018, respectively
  570   564 
Additional paid-in capital  1,632,046   1,581,144 
Accumulated deficit  (837,959)  (828,940)
Accumulated other comprehensive loss  (68,623)  (78,688)
Total stockholders’ equity  726,034   674,080 
Total liabilities and stockholders’ equity $882,249  $756,068 

(in thousands, except per share amounts)

  Three Months Ended December 31,  Year Ended December 31, 
  2019  2018  2019  2018 
Product net sales $109,019  $6,617  $310,331  $14,866 
Other revenue  57   37   1,001   533 
Total revenues  109,076   6,654   311,332   15,399 
Operating expenses                
Cost of product sales  7,298   1,829   27,199   6,644 
Research and development  43,535   29,086   142,678   146,627 
Selling, general and administrative  78,351   49,083   259,880   165,727 
Total operating expenses  129,184   79,998   429,757   318,998 
Loss from operations  (20,108)  (73,344)  (118,425)  (303,599)
Interest income  1,818   2,449   8,464   5,490 
Interest expense  (282)  (295)  (1,087)  (1,230)
Other income        104,117    
Foreign exchange loss  (5,073)  (982)  (2,272)  (6,105)
Loss before income taxes  (23,645)  (72,172)  (9,203)  (305,444)
Income tax expense (benefit)  1,301   (266)  (184)  (187)
Net loss $(24,946) $(71,906) $(9,019) $(305,257)
Net loss per share:                
Basic $(0.07) $(0.20) $(0.02) $(0.88)
Diluted $(0.07) $(0.20) $(0.02) $(0.88)
Weighted average shares outstanding:                
Basic  372,447   366,458   371,580   347,123 
Diluted  372,447   366,458   371,580   347,123 

(in thousands)

  Year Ended December 31, 
  2019  2018 
Cash flows from operating activities        
Net loss $(9,019) $(305,257)
Adjustments to reconcile net loss to net cash used in
 operating activities:
Foreign exchange loss  2,709   5,839 
Stock-based compensation  48,030   35,718 
Depreciation and amortization  9,240   9,661 
Deferred income taxes  (9,698)  (430)
Gain from sale of priority review voucher  (104,117)   
Other  39   233 
Changes in operating assets and liabilities:        
Accounts receivable, net  (44,623)  (2,706)
Inventory  (51,125)  (28,484)
Prepaid expenses and other current assets  (9,831)  11,370 
Other assets  3,888   (445)
Accounts payable  805   2,829 
Current tax liabilities  (963)  (3,966)
Accrued liabilities  43,110   19,445 
Other liabilities  (1,914)  1,423 
Net cash used in operating activities  (123,469)  (254,770)
Cash flows from investing activities        
Proceeds from sale of priority review voucher  104,117    
Additions to property, plant and equipment  (40,386)  (42,301)
Additions to capitalized software  (2,102)  (1,112)
Proceeds from disposal of property, plant and equipment     517 
Net cash provided by (used in) investing activities  61,629   (42,896)
Cash flows from financing activities        
Proceeds from issuance of ordinary shares, net of
 issuance costs
Proceeds from exercise of stock options  2,878   620 
Payments on finance leases  (389)  (251)
Payments on landlord financing obligation  (543)  (527)
Net cash provided by (used in) financing activities  1,946   324,479 
Effect of exchange rate changes on cash  5,330   5,457 
Net increase (decrease) in cash and cash equivalents  (54,564)  32,270 
Cash and cash equivalents at beginning of period  591,497   559,227 
Cash and cash equivalents at end of period $536,933  $591,497